Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

被引：1386

作者：

Brown, Christine E. ^{[1
]}

Alizadeh, Darya ^{[1
]}

Starr, Renate ^{[1
]}

Weng, Lihong ^{[1
]}

Wagner, Jamie R. ^{[1
]}

Naranjo, Araceli ^{[1
]}

Ostberg, Julie R. ^{[1
]}

Blanchard, M. Suzette ^{[2
]}

Kilpatrick, Julie ^{[3
]}

Simpson, Jennifer ^{[3
]}

Kurien, Anita ^{[1
]}

Priceman, Saul J. ^{[1
]}

Wang, Xiuli ^{[1
]}

Harshbarger, Todd L. ^{[4
]}

D'Apuzzo, Massimo ^{[5
]}

Ressler, Julie A. ^{[6
]}

Jensen, Michael C. ^{[9
]}

Barish, Michael E. ^{[7
]}

Chen, Mike ^{[4
]}

Portnow, Jana ^{[8
]}

Forman, Stephen J. ^{[1
]}

Badie, Behnam ^{[4
]}

机构：

[1] City Hope Beckman Res Inst & Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Cell Therapeut Res Lab T, Duarte, CA USA

[2] City Hope Beckman Res Inst & Med Ctr, Dept Informat Sci, Duarte, CA USA

[3] City Hope Beckman Res Inst & Med Ctr, Dept Clin Res, Duarte, CA USA

[4] City Hope Beckman Res Inst & Med Ctr, Dept Neurosurg, Duarte, CA USA

[5] City Hope Beckman Res Inst & Med Ctr, Dept Pathol, Duarte, CA USA

[6] City Hope Beckman Res Inst & Med Ctr, Dept Diagnost Radiol, Duarte, CA USA

[7] City Hope Beckman Res Inst & Med Ctr, Dept Dev & Stem Cell Biol, Duarte, CA USA

[8] City Hope Beckman Res Inst & Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA

[9] Seattle Childrens Res Inst, Ben Towne Ctr Childhood Canc Res, Seattle, WA USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2016年 / 375卷 / 26期

关键词：

INTERLEUKIN-13; PERSISTENCE; GLIOMAS; SAFETY; CARS;

D O I：

10.1056/NEJMoa1610497

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A patient with recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13R alpha 2). Multiple infusions of CAR T cells were administered over 220 days through two intracranial delivery routes - infusions into the resected tumor cavity followed by infusions into the ventricular system. Intracranial infusions of IL13R alpha 2-targeted CAR T cells were not associated with any toxic effects of grade 3 or higher. After CAR T-cell treatment, regression of all intracranial and spinal tumors was observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid. This clinical response continued for 7.5 months after the initiation of CAR T-cell therapy. (Funded by Gateway for Cancer Research and others; ClinicalTrials.gov number, NCT02208362.)

引用

页码：2561 / 2569

页数：9

共 25 条

[1]

Ahmed N., 2015, J. Immunother. Cancer, V3, pO11, DOI [10.1186/2051-1426-3-S2-O11, DOI 10.1186/2051-1426-3-S2-O11]

[2]

[Anonymous], 2016, J CLIN ONCOL

[3] Novel immunotherapies in lymphoid malignancies [J].

Batlevi, Connie Lee ;

Matsuki, Eri ;

Brentjens, Renier J. ;

Younes, Anas .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (01) :25-40

[4] Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias [J].

Brentjens, Renier J. ;

Riviere, Isabelle ;

Park, Jae H. ;

Davila, Marco L. ;

Wang, Xiuyan ;

Stefanski, Jolanta ;

Taylor, Clare ;

Yeh, Raymond ;

Bartido, Shirley ;

Borquez-Ojeda, Oriana ;

Olszewska, Malgorzata ;

Bernal, Yvette ;

Pegram, Hollie ;

Przybylowski, Mark ;

Hollyman, Daniel ;

Usachenko, Yelena ;

Pirraglia, Domenick ;

Hosey, James ;

Santos, Elmer ;

Halton, Elizabeth ;

Maslak, Peter ;

Scheinberg, David ;

Jurcic, Joseph ;

Heaney, Mark ;

Heller, Glenn ;

Frattini, Mark ;

Sadelain, Michel .

BLOOD, 2011, 118 (18) :4817-4828

[5] Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma [J].

Brown, Christine E. ;

Badie, Behnam ;

Barish, Michael E. ;

Weng, Lihong ;

Ostberg, Julie R. ;

Chang, Wen-Chung ;

Naranjo, Araceli ;

Starr, Renate ;

Wagner, Jamie ;

Wright, Christine ;

Zhai, Yubo ;

Bading, James R. ;

Ressler, Julie A. ;

Portnow, Jana ;

D'Apuzzo, Massimo ;

Forman, Stephen J. ;

Jensen, Michael C. .

CLINICAL CANCER RESEARCH, 2015, 21 (18) :4062-4072

[6] Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine-Redirected T Cells [J].

Brown, Christine E. ;

Starr, Renate ;

Aguilar, Brenda ;

Shami, Andrew F. ;

Martinez, Catalina ;

D'Apuzzo, Massimo ;

Barish, Michael E. ;

Forman, Stephen J. ;

Jensen, Michael C. .

CLINICAL CANCER RESEARCH, 2012, 18 (08) :2199-2209

[7]

Cerny C., 2015, INT TRENDS IMMUNITY, V3, P19, DOI [10.18281/iti.2015.2.3, DOI 10.18281/ITI.2015.2.3]

[8] Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia [J].

Davila, Marco L. ;

Riviere, Isabelle ;

Wang, Xiuyan ;

Bartido, Shirley ;

Park, Jae ;

Curran, Kevin ;

Chung, Stephen S. ;

Stefanski, Jolanta ;

Borquez-Ojeda, Oriana ;

Olszewska, Malgorzata ;

Qu, Jinrong ;

Wasielewska, Teresa ;

He, Qing ;

Fink, Mitsu ;

Shinglot, Himaly ;

Youssif, Maher ;

Satter, Mark ;

Wang, Yongzeng ;

Hosey, James ;

Quintanilla, Hilda ;

Halton, Elizabeth ;

Bernal, Yvette ;

Bouhassira, Diana C. G. ;

Arcila, Maria E. ;

Gonen, Mithat ;

Roboz, Gail J. ;

Maslak, Peter ;

Douer, Dan ;

Frattini, Mark G. ;

Giralt, Sergio ;

Sadelain, Michel ;

Brentjens, Renier .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)

[9]

Debinski W, 1999, CLIN CANCER RES, V5, P985

[10]

Debinski W, 1999, CLIN CANCER RES, V5, p3143S

← 1 2 3 →